What Ali Parsa and Iman Abuzeid teach us about the real cost of conviction
Buyers don't pay for conviction. They pay for conviction with proof behind it, and no two stories teach that lesson better than Ali Parsa's and Iman Abuzeid's.
Dr. Roxie Mooney, DBA releases Winning in Healthcare: How the Best Builders Turn Growth Into Enterprise Value
Winning in Healthcare names a problem many healthcare leaders feel but few can explain: a company can grow revenue and build real momentum, and still watch its valuation fall behind.
Dr. Roxie Mooney argues that gap is rarely a growth problem. It is a structure, narrative, and transferability problem, and the most expensive issue a healthcare company can fail to see from the inside.
“Winning in Healthcare” is here: What's inside and why we wrote it
Today, Winning in Healthcare: How the Best Builders Turn Growth into Enterprise Value by our founder, Dr. Roxie Mooney, DBA, is officially available.
In the foreword, Mark Montgomery, former BioPlus Specialty Pharmacy CEO whose story closes the book, describes exactly what we set out to build:
"The next generation of healthcare leaders doesn't need another book about inspiration. They need a book about construction. How you build something real. How you make it scalable. How you make it something that can outlive you." — Mark Montgomery, Former CEO, BioPlus Specialty Pharmacy
A book about construction. That's precisely what this is.
Meet the 11 builders behind Winning in Healthcare: How the Best Builders Turn Growth Into Enterprise Value
Most healthcare companies don't fail because the idea was wrong. They fail because no one built the system required to survive success.
That line sits at the center of Winning in Healthcare: How the Best Builders Turn Growth Into Enterprise Value, releasing soon from Legacy DNA Press.
The gap between growth and enterprise value
Revenue is up. The team is growing. The product works. By every visible measure, the business looks healthy.
But ask a buyer to look closely, and a different story often shows up.
You found product-market fit. Why did growth slow down?
Roughly 4 in 5 companies that hit product-market fit still fail to scale it. The difference comes down to whether the commercial system was ever built to carry the weight.
The same founder who built your growth may be quietly capping your valuation
Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.
What got you here won't get you there
Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.
Stop chasing the 97%
Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.
Healthcare marketing doesn’t have to feel like a fire drill. And yet.
Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.
16 years of building what lasts
Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.
From ACA to AI: What sixteen years of healthcare disruption actually taught us
Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.
16 Lessons healthcare companies learn too late
Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.
You're growing. Your valuation isn't.
Revenue growth can mask structural fragility — when performance isn’t systematized, buyers discount valuation because they can’t underwrite what won’t scale or transfer.
Narrative debt: The hidden cost in your healthcare valuation
In this article, we define narrative debt, explain why late-stage story work can only limit the damage, and lay out what healthcare CEOs should be doing now to resolve it before it affects their valuation.
Brand leadership & market authority: Align your market position with enterprise value
Build the kind of brand investors believe in. Let’s start aligning your market position with your enterprise value.
AI-powered growth operations: Where data intelligence meets human precision
At Legacy DNA, we integrate artificial intelligence as an acceleration tool, not a replacement for expertise.
From operationally strong to acquisition-ready: How Axium turned performance into a buyer-ready platform
Inside the transformation that turned strong operations into a clear commercial story, strengthened buyer confidence, and helped position Axium for successful acquisition.
From overlooked to irresistible: How BioPlus became a $2B growth story
Inside the transformation that doubled revenue, redefined a category, and led to multiple premium acquisitions.
From pain to power: How Hinge Health built a category buyers could not ignore
Inside the journey from personal conviction to market dominance and what every healthtech CEO can learn about Exit Readiness.